The IQWiG commenced its asssessment of abacavir sulfate with dolutegravir sodium and lamivudine (Triumeq) on 12 September 2014.  The European Commission approved the use of Triumeq for the treatment of human immunodeficiency virus infection in adults and adolescents from 12 years of age weighing at least 40 kg on 1 September 2014.

For more details, go to: https://www.iqwig.de/de/projekte-ergebnisse/projekte/arzneimittelbewertung/a14-34-dolutegravir/abacavir/lamivudin-nutzenbewertung-gemass-35a-sgb-v-dossierbewertung.6370.html?&et_cid=4&et_lid=%25208 [German]